343 episodes

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

The Bio Repor‪t‬ The Bio Report

    • Investing
    • 3.9 • 31 Ratings

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

    A Small Molecule Cancer Drug That Promotes an Adaptive Immune Response

    A Small Molecule Cancer Drug That Promotes an Adaptive Immune Response

    Phosplatin Therapeutics is developing a class of small molecule cancer therapies designed to avoid the problems of drug resistance and toxicity associated with chemotherapies. The company’s lead experimental therapy is a first-in-class small molecule that promotes immunogenic cell death, a type of cell death that elicits an immune response. We spoke to Matthew Price, co-founder, executive vice president, and chief operating officer of Phosplatin, about the company’s lead therapy, its multiple mechanisms of action, and why it may have benefit in a broad range of cancers.

    • 29 min
    Sloan-Kettering Spin-Out Harnesses AI to Diagnose Cancer

    Sloan-Kettering Spin-Out Harnesses AI to Diagnose Cancer

    Earlier this year Paige, a company developing artificial-intelligence driven pathology platforms for the diagnosis of cancer, raised $100 million in a series C venture round. The funding came a month after the company, a spin-out of Memorial Sloan Kettering Cancer Center, scored its first two European approvals for its breast cancer and prostate cancer offerings. We spoke to Leo Grady, CEO of Paige, about how the company’s artificial intelligence platform works, why it may lead to the identification of new biomarkers, and the potential for AI to change the way cancer patients are diagnosed.

    • 26 min
    Bringing Innovation to Cell and Gene Therapy Manufacturing

    Bringing Innovation to Cell and Gene Therapy Manufacturing

    While cell and gene therapies represent an area of great therapeutic promise, current manufacturing process are expensive and difficult to scale. As a result, this creates bottlenecks that limit patient access to these therapies and hamper the growth of the sector. Ori Biotech has developed an automated and scalable manufacturing platform for cell and gene therapies that seeks to increase capacity and quality while reducing costs. We spoke to Farlan Veraitch, co-founder and chief scientific officer of Ori, about the challenges of manufacturing cell and gene therapies, how the company’s platform addresses those issues, and why it is initially focusing on CAR-T cell therapies.

    • 22 min
    Tapping Psychedelics for their Anti-Inflammatory Powers

    Tapping Psychedelics for their Anti-Inflammatory Powers

    There’s been a growing industry effort to explore the use of psychedelics for their medicinal benefits. While much of these efforts have looked to these drugs to treat a range of psychiatric conditions, Eleusis sees a broader potential for them. While the company is pursuing psychedelics as potential treatments for major depressive disorder, it also is developing psychedelic candidate in other indications because of their anti-inflammatory properties. We spoke to Shlomi Raz, CEO of Eleusis, about of the case for psychedelics as treatments for inflammatory conditions, how they work, and what challenges the development of these drugs pose.

    • 31 min
    Advancing Cell Therapies Beyond Cancer

    Advancing Cell Therapies Beyond Cancer

    Regulatory T cell therapies have been pursued as treatment for cancers, but Sonoma Biotherapeutics believes these cells can be harnessed to delivery lasting and potential curative treatments for autoimmune and degenerative diseases. We spoke to Jeff Bluestone, CEO of Sonoma, about regulatory T cell therapies, why they may have broad application in a range of conditions, and what challenges will need to be overcome to usher in an area of cell therapies beyond cancer.

    • 19 min
    How the Pandemic Transformed a Small Diagnostics Company

    How the Pandemic Transformed a Small Diagnostics Company

    For more than 15 years, Longhorn Vaccines & Diagnostics has been designing and developing products for potential pandemics in developing economies. The recent COVID-19 pandemic, though, put the scalability of the company’s technology to the test as it landed big contracts in the United States for COVID-19 testing. We spoke to Jeff Fischer, president of Longhorn, about the benefits of the company’s technology for gathering and transporting diagnostic samples, how it’s used partnerships to scales it business with speed, and why the pandemic has forever changed the company.

    • 21 min

Customer Reviews

3.9 out of 5
31 Ratings

31 Ratings

Inrater ,

Good content

I am a longtime investor in Biotech and find the topics and interviews extremely interesting. The sound is not that good but it really doesn’t matter when the content is interesting. I would shorten the intro jingle by 50%. Keep up the good work.

Juliana621 ,

Not for physicians

I’m a physician doing translational research in gene therapy. At least for the medical part the interviews discuss inaccurate information. For example there’s a talk where the interviewee says that in medicine therapy for most or all diseases are only symptom based “...such as diabetes and cancer...” which is absolutely wrong as especially in these diseases therapy starts as early as possible specifically to prevent symptoms. In addition there are some interviews where it seems that the members of the discussion haven’t discussed before hand what points will be touched and sometimes the interviewee “corrects the interviewer” which makes listening confusing. I’m unsubscribing and will search for other translational gene therapy research podcasts.

bman90254 ,

Paid for advertising?

I can see the relevance for investors to hear these advertisements, however, as a scientist I fail to see the value.

Top Podcasts In Investing

Listeners Also Subscribed To